1-(2-(2-fluoro-4-nitrophenoxy)ethyl)pyrrolidine | 943189-36-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-(2-fluoro-4-nitrophenoxy)ethyl)pyrrolidine
• 英文别名: 1-(2-((2-fluoro-4-nitrophenyl)oxy)ethyl)pyrrolidine；1-{2-[(2-fluoro-4-nitrophenyl)oxy]ethyl}pyrrolidine；1-[2-(2-fluoro-4-nitro-phenoxy)-ethyl]-pyrrolidine；1-[2-(2-fluoro-4-nitrophenoxy)ethyl]pyrrolidine
• CAS: 943189-36-4
• 化学式: C₁₂H₁₅FN₂O₃
• 分子量: 254.261
• InChiKey: INZRDRWRCZWASO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(2-(2-fluoro-4-nitrophenoxy)ethyl)pyrrolidine 在 4-二甲氨基吡啶 、 palladium on activated charcoal 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 36.0h， 生成 N-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)phenyl]-3'-hydroxybiphenyl-3-carboxamide
  参考文献：
  名称：

  Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: Design, synthesis and 3D-QSAR studies

  摘要：

  VEGFR-2 plays an essential role in angiogenesis and is a central target for anticancer drug discovery. In order to develop novel VEGFR-2 inhibitors, we designed and synthesized 33 biphenyl amides based on our previously reported lead compound. The biological results indicated that four compounds (18b, 20e, 20h and 20j) are potent VEGFR-2 inhibitors which are comparable to positive control. Compound 18b displayed the most potent VEGFR-2 inhibition with IC50 value of 2.02 nM. Moreover, it exhibited promising antiproliferative activity against MCF-7 and SMMC-7721 cells with IC50 values of 1.47 mu M and 5.98 mu M, respectively. Molecular docking and 3D-QSAR studies were also carried out. The results indicated that these biphenyl amides could serve as promising leads for further optimization as novel VEGFR-2 inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.01.006
• 作为产物：
  描述：

  N-(2-羟乙基)-吡咯烷 、 3,4-二氟硝基苯 在 C12H15FN2O3 作用下， 生成 1-(2-(2-fluoro-4-nitrophenoxy)ethyl)pyrrolidine
  参考文献：
  名称：

  NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

  摘要：

  本发明涉及氨基醇取代的芳基噻唑嘧啶酮及其衍生物、其生理上可耐受的盐和生理功能衍生物、其制备方法、包含本发明中至少一种氨基醇取代的芳基噻唑嘧啶酮或其衍生物的药物以及将本发明中的氨基醇取代的芳基噻唑嘧啶酮及其衍生物用作MCH拮抗剂的用途。

  公开号：

  US20090076002A1

文献信息

• [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009076140A1

  公开（公告）日：2009-06-18

  The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑和恶唑化合物、含有该化合物的组合物，以及它们的制备方法和作为药物的应用方法。
• [EN] THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE THIAZOLE SULFONAMIDE ET OXAZOLE SULFONAMIDE KINASES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010104899A1

  公开（公告）日：2010-09-16

  The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents

  本发明提供了噻唑磺酰胺和恶唑磺酰胺化合物、含有该化合物的组合物，以及它们的制备方法和作为药物的使用方法。
• [EN] BRD4-JAK2 INHIBITORS<br/>[FR] INHIBITEURS DE BRD4-JAK2
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2020051572A1

  公开（公告）日：2020-03-12

  Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

  本文披露了一些抑制BDR4的化合物及其在癌症治疗中的应用。还披露了筛选BDR4选择性抑制剂的方法。在某些方面，披露了公式I至IV的化合物。
• Pyrrolopyrimidinyl axl kinase inhibitors
  申请人：Vankayalapati Hariprasad

  公开号：US20100204221A1

  公开（公告）日：2010-08-12

  Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with Axl kinase. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.

  由公式（I）表示的化合物在治疗通过Axl激酶介导和/或相关（至少部分相关）的疾病，如癌症方面具有用处。这些化合物可以制备成药学上可接受的组合物，用于给需要的受试者。
• Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors
  申请人：Bold Guido

  公开号：US20080312248A1

  公开（公告）日：2008-12-18

  The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

  本发明涉及公式IA的杂环芳基基脲化合物，其中基团和符号的含义如本文所定义，这些化合物在蛋白激酶依赖性疾病的治疗中的使用；含有上述杂环芳基基脲化合物的制药制剂；制备这些新化合物的方法以及使用这些杂环芳基基脲化合物的治疗方法。